Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

SABA vs NMTC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NMTC Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 5–3 Matrix Metrics)

NMTC Overall Winner 6-Pillar Tally: SABA 0 – 5 NMTC (1 Tie) Matrix Metrics: SABA 3 – 5 NMTC

As of Nov 20, 2026, NeuroOne Medical Technologies Corporation (NMTC) is the stronger overall head-to-head candidate over Saba Capital Income & Opportunities Fund II (SABA) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SABA carries a Unified Composite Score of 44.2/100 (HOLD) at $7.33 (N/M Forward P/E, N/A operating margin), whereas NMTC carries 45.5/100 (HOLD) at $0.65 (N/M Forward P/E, -63.4% operating margin).

  • Technical & Structure Timing Caution: SABA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.9); meanwhile NMTC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SABA vs NMTC
SABA NYSE
Saba Capital Income & Opportunities Fund II
Institutional Equity
$7.33
-0.27% 1D
Market Cap $251.8M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.37β · 13% Vol
Unified Composite Score
44.2 / 100 HOLD
Tech 38.0 Fund 55.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.2%), weak momentum, RSI 30
RSI-14: 29.9 · SMA20: $7.56 · SMA50: $7.75
NMTC NASDAQ Head-to-Head Winner
NeuroOne Medical Technologies Corporation Common Stock
Surgical & Medical Instruments & Apparatus
$0.65
-3.38% 1D
Market Cap $6.1M
TTM Revenue $12M
Forward P/E N/M
Beta / 30D Vol 1.55β · 105% Vol
Unified Composite Score
45.5 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 60.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -28.4%), weak momentum, RSI 31
RSI-14: 31.2 · SMA20: $0.83 · SMA50: $1.03

6-Pillar Scorecard Institutional Category Breakdown (SABA 0 – 5 NMTC)

Columns: Metric · SABA · NMTC
1. Valuation Multiples NMTC
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 0.3x
2. Growth & Scale NMTC
Revenue Growth (YoY) N/A +16.3%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $12M
Market Cap $251.8M $6.1M
3. Profitability & Quality NMTC
Gross Margin N/A 23.0%
Operating Margin N/A -63.4%
Net Profit Margin N/A -59.7%
Return on Equity (ROE) N/A -124.7%
4. Balance Sheet & Cash Flow NMTC
Cash Generation (TTM) N/A -$7.6M
Cash Flow Margin N/A -60.7%
Net Cash / Leverage N/A ROE $2.6M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning NMTC
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SABA (3) vs NMTC (5)
Institutional Metric SABA NMTC Criterion Row Edge
Market Capitalization
Scale
$251.8M $6.1M Larger Scale SABA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +16.3% Higher Growth NMTC
Operating Margin (TTM)
Profitability
N/A -63.4% Higher Margin NMTC
Net Profit Margin
Profitability
N/A -59.7% Higher Margin NMTC
Return on Equity (ROE)
Capital Efficiency
N/A -124.7% Higher ROE NMTC
52-Week Range Position
Momentum
4% ($7–$9) 2% ($1–$5) Stronger Trend SABA
Beta / 30D Volatility
Risk Regime
0.37β · 13% Vol 1.55β · 105% Vol Lower Realized Risk SABA
Unified Institutional Score
Composite Signal
44.2 / 100 (HOLD) 45.5 / 100 (HOLD) Higher Composite NMTC
Trailing 12M Revenue (USD)
Operating Scale
N/A $12M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 23.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 0.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$7.6M ($2.6M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SABA +29.78 pp
SABA: -3.68% · NMTC: -33.46%
3M Horizon SABA +59.03 pp
SABA: -10.5% · NMTC: -69.53%
6M Horizon SABA +69.49 pp
SABA: -12.84% · NMTC: -82.33%
1Y Horizon NMTC +19.53 pp
SABA: -16.04% · NMTC: +3.49%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SABA vs NMTC. Trailing 12-month operating profitability (SABA N/A vs NMTC -63.4%) and valuation multiples (SABA N/M vs NMTC N/M Forward P/E) are benchmarked directly in Pillar 4 below.

SABA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
NMTC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$12M
Gross Margin23.0%
Op. Margin-63.4%
ROE / Fwd P/E-124.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SABA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SABA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NMTC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NMTC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SABA Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with $251.8M market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NMTC Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.1M market capitalization and -63.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SABA vs NMTC Key Questions & Quantitative Answers

As of Nov 20, 2026, NeuroOne Medical Technologies Corporation (NMTC) is the stronger overall head-to-head candidate over Saba Capital Income & Opportunities Fund II (SABA) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SABA carries a Unified Composite Score of 44.2/100 (HOLD) at $7.33 (N/M Forward P/E, N/A operating margin), whereas NMTC carries 45.5/100 (HOLD) at $0.65 (N/M Forward P/E, -63.4% operating margin). Technical & Structure Timing Caution: SABA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.9); meanwhile NMTC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NMTC leads the Growth & Scale pillar: SABA posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with NMTC at +16.3% YoY revenue growth and +0.0% YoY earnings growth on $12M TTM revenue (23.0% gross margin, -63.4% operating margin). On trailing 12-month operating scale, SABA generates N/A in USD-normalized revenue versus $12M for NMTC. In operating R&D and SG&A reinvestment, SABA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NMTC.

NMTC screens cheaper on headline valuation multiples. SABA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas NMTC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-60.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SABA (N/A ROE) versus NMTC (-124.7% ROE) capital efficiency.

In options market volatility and institutional positioning, SABA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.37β · 13% Vol realized risk). By comparison, NMTC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.55β · 105% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.